Business
Roadman Acquisition Target CLOV Biopharma Corp. Expedites Corporate Initiatives In Response To Continued Global Spread of COVID-19
(via TheNewswire) March 2, 2020 - TheNewswire - Vancouver , British Columbia - Ro...
About this update from Futuregen Industries Corp.
[{"type":"text","content":"Roadman Acquisition Target CLOV Biopharma Corp. Expedites Corporate Initiatives In Response To Continued Global Spread of COVID-19(via TheNewswire)\n \n \nMarch 2, 2020 - TheNewswire - Vancouver, British Columbia - Roadman Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF) (\"Roadman Investments\" or the \"Company\") is pleased to announce that, the Company's pending acquisition target, CLOV Biopharma Corp. (\"CBP\"), confirms that it has made an expedited order of certified premium cedar leaf oil under its exclusive licensing agreement so as to expedite its research and development efforts. Additionally, CBP has procured various prototype diffuser units in order test their compatibility and efficiency with its cedar leaf oil vapour (\"CLOV\") compound. Upon receipt, CBP shall focus on:\n\n\n \n\n\n- Continuing studies into killing (inactivating) human respiratory viruses including Influenza, Rhinovirus, Adenovirus, Herpes simplex virus, and coronaviruses includling COVID-19\n\n\n\n- Efficiency testing of the CBP stationary and hand-held diffuser units\n\n\n\n- Branding, packaging and labeling of the diffuser units and CLOV compound formulations\n\n\n\n- Securing an initial purchase order for CBP diffuser units\n\n\n\n- Shipment of CLOV compound internationally for lab and quality control testing\n\n\n\n\n \n\nWith the acceleration of the COVID-19 virus which, according to the WHO (https://www.who.int/emergencies/diseases/novel-coronavirus-2019), is now in over 57 countries, with 89,000 confirmed cases and currently over 2,900 deaths, including the first reported death in the United States over the weekend, the search for additional safe and effective methods to protect personal environments from viruses and pathogens is increasing at a rapid rate. In an effort to expedite its corporate mandate of advancing the research and potential commercial viability of cedar leaf oil vapour specifically in the pharmaceutical, healthcare, and biotechnology sectors, CBP has fast tracked additional procurement of certified cedar leaf oil for immediate receipt and testing. CBP has received inbound requests from various international and domestic enterprises that are desirous of obtaining CLOV samples for research purposes. Concurrently, from a consumer standpoint, CBP has fielded increased requests for personal dispensing diffuser devices. In ...